Price T Rowe Associates Inc Agios Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,777,259 shares of AGIO stock, worth $127 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,777,259
Previous 2,012,993
37.97%
Holding current value
$127 Million
Previous $58.9 Million
103.46%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding AGIO
# of Institutions
226Shares Held
56.3MCall Options Held
275KPut Options Held
251K-
Farallon Capital Management LLC San Francisco, CA5.65MShares$258 Million1.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.5MShares$251 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$222 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.88MShares$177 Million2.8% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.2MShares$100 Million0.03% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.5B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...